Table 1 Baseline patient characteristics at intensive care unit admission and at inclusion
From: Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock
Characteristics | Total (n = 110) | Amikacin C max (mg/L) | P | ||
|---|---|---|---|---|---|
<60 (n = 20) | 60–80 (n = 46) | >80 (n = 44) | |||
At ICU admission | |||||
Age (years old) | 61 [51–70] | 57. 5 [50.5–69] | 63 [45–69] | 62 [55.5–70] | 0.521 |
Male sex | 78 (70.9) | 14 (70) | 33 (71.7) | 31 (70.5) | 0.986 |
Weight (kg) | 70 [58.2–80] | 60 [52.5–73.5] | 70 [58.2–80] | 72.5 [65–82] | 0.029 |
Body mass index (kg/m2) | 24.6 [20.7–28] | 21.1 [18.5–25.7] | 23.7 [20.8–27.3] | 26.6 [21.9–29] | 0.023 |
APACHE II | 23 [18–28] | 25 [21–28] | 23 [17–28] | 22 [18–26] | 0.309 |
Simplified Acute Physiology Score 2 | 54 [41–68] | 62 [47–70] | 54 [44–63] | 52 [40–67] | 0.361 |
History of congestive heart failure | 12 (10.9) | 1 (5) | 8 (17.4) | 3 (6.9) | 0.177 |
Liver cirrhosis | 4 (3.6) | 0 | 2 (4.3) | 2 (4.5) | 0.63 |
Chronic obstructive pulmonary disease | 26 (23.6) | 5 (25) | 10 (21.7) | 11 (25) | 0.924 |
Chronic kidney disease requiring dialysis | 9 (8.2) | 1 (5) | 2 (4.3) | 6 (13.6) | 0.233 |
Cancer (<3 months) | 16 (14.5) | 4 (20) | 10 (21.7) | 2 (4.5) | 0.051 |
Diabetes mellitus | 39 (35.5) | 7 (35) | 12 (26.1) | 20 (45.5) | 0.158 |
Immunodepression | 24 (21.8) | 6 (30) | 9 (19.6) | 9 (20.5) | 0.616 |
At the day of aminoglycoside administration | |||||
Day since admission | 1 [0–5] | 1 [0–6] | 0.5 [0–5] | 1.5 [0–6.5] | 0.834 |
Emergent surgery | 25 (22.7) | 9 (45) | 12 (26.1) | 4 (9.1) | 0.005 |
Sequential Organ Failure Assessment score | 10 [8–11] | 10 [9–11] | 10 [7–12] | 10 [8–12] | 0.950 |
Weight (kg) | 70 [60–80] | 66 [55.5–79] | 71 [58.2–80] | 72 [65.5–82] | 0.104 |
Weight gain since ICU admission (kg) | 0 [0–3] | 0 [0–3] | 0 [0–2] | 0 [0–2] | 0.847 |
Extracorporeal membrane oxygenation | 15 (13.6) | 4 (20) | 5 (10.9) | 6 (13.6) | 0.611 |
Catecholamines | 89 (80.9) | 16 (80) | 36 (78.3) | 37 (84.1) | 0.776 |
Norepinephrine (µg/kg/min) | 0.44 [0.1–0.93] | 0.88 [0.11–1.64] | 0.46 [0.09–0.83] | 0.41 [0.11–0.81] | 0.343 |
PaO2/FiO2 ratio | 177 [122–264] | 155 [90–230] | 203 [140–289] | 159 [118–258] | 0.234 |
Renal replacement therapy | 40 (36.4) | 12 (60) | 15 (32.6) | 13 (29.5) | 0.05 |
Glomerular filtration rate (mL/min) | 45 [18.6–86.2] | 22.1 [0–90.4] | 43.6 [24.6–86] | 49.7 [22.5–83.9] | 0.583 |
Lactate level (mmol/L) | 2.3 [1.2–4] | 2.7 [1.5–4] | 2.3 [1.2–6.5] | 1.7 [1.2–3.2] | 0.315 |
Platelet count (G/L) | 204 [97–307] | 170 [84–218] | 204 [90–340] | 230 [141–325] | 0.113 |
Hematocrit level (%) | 29.3 [26–31.6] | 30.3 [26.8–32.7] | 29.7 [27.3–31.6] | 27.7 [25.3–31.1] | 0.284 |
Leucocyte count (G/L) | 13.9 [8.9–21] | 14.1 [7.1–17.7] | 15.6 [8.9–23.2] | 13 [9.2–20.3] | 0.373 |
Glasgow Coma Scale score | 15 [13–15] | 15 [13–15] | 15 [13–15] | 15 [13–15] | 0.661 |
Bilirubin level (mg/dL) | 12 [8–20] | 12.5 [9–20] | 12 [9–29] | 12 [7–19] | 0.657 |
Prothrombin time (%) | 66 [52–78] | 66 [57–78] | 64 [47–81] | 67 [57–78] | 0.606 |
Proteinemia (g/L) | 56 [47–63] | 46.5 [40.5–60.5] | 55.5 [49–64] | 59 [51–64.5] | 0.007 |